Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Guideline for the diagnosis and management of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I)
Jason DabbsMerrill Wealth ManagementMobileAlabama$1M$1.3B$2.5-45M$1.5-4.5MLaurie RussellMerrill Wealth ManagementMontgomeryAlabama$500K$588M$5-500M$2.5-15MTracy HorneMerrill Wealth ManagementMontgomeryAlabama$250K$175M$1-5M$500K-3MAlexander TovarWells Fargo AdvisorsBirminghamAlabama$500K$394M$1-5M$500K-4.5MCindy ClarkMerrill Wealth ManagementMontgomeryAlabama$250K$370M$1-2.5M$500K-1.2MLee ClarkMorgan Stanley Wealth ManagementDecaturAlabama$1M$502M$1-10M$800K-6MJennifer RyderAmeriprise Financial ServicesMobileAlabama$250K$526M$300K-1M$200-700KJohn GreggWells Fargo AdvisorsBirminghamAlabama$250K$276M$1-10M$500K-5MCharles Harris JonesMerrill Wealth ManagementHuntsvilleAlabama$250K$317M$500K-3.5M$650K-7MJohn FergusonClarity Private Wealth | Steward PartnersMobileAlabama$2.5M$300M$2.5-100M$2.5-50MG
As of now, there's no definitive date for when Retatrutide will be commercially available
Both compounds are full cAMP agonists at GIPR
The benzyl alcohol preservative helps with microbial control, but it does not prevent all chemical degradation
US$ 24.09
US$ 24.67
US$ 23.53
US$ 21.51
US$ 28.87
